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ABSTRACT 
 In this work, we have examined the possible role of AMP-activated protein 
kinase (a key energy sensor) in regulating intracellular protein degradation. We have 
found that AICAR, a known activator of AMPK, has a dual effect. On one hand, it 
inhibits autophagy by a mechanism independent of AMPK activity; AICAR decreases 
class III PI3-kinase binding to beclin-1 and this effect counteracts and reverses the 
known positive effect of AMPK activity on autophagy. On the other hand, AICAR 
inhibits the proteasomal degradation of proteins by an AMPK-dependent mechanism. 
This is a novel function of AMPK that allows the regulation of proteasomal activity 
under conditions of energy demand. 
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INTRODUCTION 
 Intracellular protein degradation is a catabolic process by which all intracellular 
proteins in prokaryotic and eukaryotic cells are continuously broken down [1]. The 
major sites of intracellular protein degradation in mammalian cells are the proteasomes 
and the lysosomes. Both degrade proteins by energy-consuming processes requiring 
ATP ([2], [3]). Therefore, intracellular protein degradation is a highly energy-
demanding process and, thus, it is expected that under conditions of energy depletion 
this process should be tightly regulated. In fact, this is the case for the proteasomal 
protein degradation pathway, where it has been found that prolonged starvation or 
severe heat shock conditions promote proteasome dissociation, resulting in a rapid 
decline in intracellular proteolysis ([4], [5]). However this rationale is not that evident 
for lysosomal protein degradation, since it has been reported that this process is 
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activated by various stress situations, including nutrient depletion. This may be 
explained because under these stress conditions, autophagy provides constituents 
required to maintain the essential metabolism for survival [6]. 
AMP-activated protein kinase (AMPK) is a conserved sensor of cellular energy 
which protects cells by acting as a low-fuel warning system. AMPK is a heterotrimer 
composed of three different subunits, i.e. ,  and . AMPK is the catalytic subunit 
(with two isoforms 1 and 2), whereas AMPK (with two isoforms 1 and 2) and 
AMPK (with three isoforms 1, 2 and 3) play regulatory roles. The activity of 
AMPK is regulated by phosphorylation of the catalytic alpha subunit at Thr172 by an 
upstream kinase, sharing LKB1 and CaMKK this role (see [7] for review). Since 
AMPK is a sensor of cellular energy, it seems plausible that AMPK may play a role in 
the regulation of intracellular protein degradation. In fact, it is known that the yeast 
orthologue of AMPK (Snf1) stimulates autophagy in yeast [8]. However, in isolated 
hepatocytes, initial reports using 5-aminoimidazole-4-carboxamide 1--D-
ribofuranoside (AICAR) as an activator of AMPK [9], suggested that AMPK had the 
opposite effect [10]. Nevertheless, more recent reports clearly indicate that AMPK, like 
its yeast Snf1 counterpart, has a positive effect on autophagy ([11], [12], [13]). 
 The purpose of this work was to examine the effect of AMPK on the main 
proteolytic pathways in human fibroblasts. To this end, we used AICAR as an activator 
of AMPK function and found that this compound can prevent intracellular protein 
degradation by two mechanisms, one which decreases the amount of autophagic 
vacuoles by interfering with the function of class III PI3-kinase, and another preventing 
proteasome function. We also demonstrate that the effect of AICAR on lysosomes is 
independent of AMPK action, whereas its effect on proteasomes depends on AMPK 
activity. 
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MATERIALS AND METHODS 
Cell culture 
 Healthy human skin fibroblasts (3349B) were obtained from the Coriell Institute 
for Medical Research (Camden, NJ) and grown in MEM (Sigma, St. Louis, MO) with 
Earle’s salts as described [14]. AMPK subunit double knockout mouse embryonic 
fibroblasts (MEFs) (1-/- and 2-/-) and wild type controls were grown as described 
previously [15]. 
 
Adenovirus infection 
 Adenovirus encoding a dominant negative form of AMPK (Ad-DN-AMPK; 
AMPK1 D157A), a constitutively active AMPK form (Ad-CA-AMPK; AMPK11-312 
T172D), or encoding GFP (Ad-GFP), all kindly provided by Dr. P. Ferré and Dr. F. 
Foufelle (INSERM Unit 671, Université Paris 6, Centre de Recherches Biomedicales 
des Cordeliers, Paris, France), were propagated as described in [16]. 
 
Measurements of intracellular protein degradation by pulse-chase experiments. 
 Fibroblasts were incubated for 48h in fresh complete medium with 5 Ci/ml 
[3H]valine (Amersham Biotech; Piscataway, NJ) and then chased for 24h in fresh 
complete medium containing 10 mM L-valine. To measure protein degradation, cultures 
were incubated for 4h in Krebs-Henseleit medium and protein degradation was analyzed 
as in [14]. 
 
Immunoblot analysis. 
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 Cell lysates were prepared as in [14]. Sixty g of total protein from cell lysates 
were analyzed by SDS-PAGE and western blotting using the appropriate antibodies: 
anti-phospho-T172-AMPK, anti-AMPK, anti-phospho-S473-Akt, anti-Akt, were from 
Cell Signaling Technology (Beverly, MA); anti-PI3-kinase class III and anti-GFP were 
from Abcam (Cambridge, UK); monoclonal anti-beclin (clone12B4) and anti-LC3 
(clone 5F10) were from Nanotools (Teningen, GER). The secondary antibodies coupled 
to horseradish peroxidase and the anti-actin antibodies were from Sigma (St. Louis, 
MO). 
 
Electron microscopy. 
 Preparation of samples for electron microscopy and morphometric 
measurements were carried out as detailed in [17]. For each condition, about thirty 
different electron micrographs from four different samples were analyzed. 
 
Determination of proteasome activity. 
 Wild type and AMPK subunit double knockout (1-/- and 2-/-) MEFs 
(35,000 cells) were cultivated in DMEM medium (Lonza Bioscience, Barcelona). Then, 
they were incubated for 4 h in Krebs-Henseleit medium containing or not 0.5 mM 
AICAR, 2 mM metformin or 20 M lactacystin. Finally, the chymotrypsin-like activity 
of proteasomes was measured using the Proteasome-Glo Cell-Based Assay with N-Suc-
LLVY-aminoluciferin as substrate (Promega, Madison, WI), following the 
manufacturer’s instructions. Luminiscence was measured in a Spectra Max M5 
microplate reader (Molecular Devices, Sunnyvale, CA). Results were referred to the 
activity found in wild type MEFs cells growing in Krebs-Henseleit medium without 
additions. 
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Statistical data analysis. 
Data are expressed as means ± standard deviation (SD). Statistical significance 
of differences between the groups was evaluated by a paired Student’s t test with two-
tailed distribution. The significance has been considered at * p<0.05, ** p<0.01 and *** 
p<0.001, as indicated in each case. 
 
RESULTS 
1) AICAR treatment prevents protein degradation by both proteasomal- and 
lysosomal-independent mechanisms. 
 To explore a possible role of AMPK in protein degradation we measured the 
degradation of radiolabeled proteins in human fibroblasts under conditions of AMPK 
activation. To differentiate protein degradation mediated by proteasomal and lysosomal 
pathways, we treated the cells with either lactacystin (a proteasomal inhibitor) or a 
mixture of ammonium chloride and leupeptin (NH4/Leup; which inhibit lysosomal-
dependent degradation). As shown in Fig. 1, lactacystin inhibited about 1/3 of total 
protein degradation, whereas NH4/Leup made a reduction of around 2/3. The combined 
treatment of lactacystin plus NH4/Leup prevented almost completely protein 
degradation. Then, we treated the cells with AICAR (an AMPK activator; [9]), alone or 
in combination with the other treatments described above. We observed that AICAR 
reduced protein degradation by 43%, in agreement with previous reports ([10], [11]). 
The combined action of AICAR plus lactacystin made an extra 18% reduction in protein 
degradation respect to the levels obtained with lactacystin alone, indicating that AICAR 
was able to inhibit protein degradation by a non-proteasomal mechanism. In the same 
way, the combined action of AICAR plus NH4/Leup made an extra 7% reduction in 
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protein degradation respect to the levels obtained with NH4/Leup alone, indicating that 
AICAR was able to inhibit protein degradation by a non-lysosomal mechanism. 
 
2) The proteasomal-independent inhibitory properties of AICAR occur by an 
AMPK-independent mechanism. 
 As expected, AICAR treatment induced the phosphorylation of AMPK at the 
Thr172 residue, a sign of AMPK activation (Fig. 2A, lanes corresponding to uninfected 
cells). In order to assess whether the inhibitory properties of AICAR on protein 
degradation were related to activation of AMPK, we infected fibroblasts with an 
adenovirus expressing a dominant negative form of AMPK (Ad-DN-AMPK, AMPK1 
D157A; kindly provided by Dr. Pascal Ferre and Dr. F. Foufelle) to prevent AMPK 
activity, or with an adenovirus expressing GFP (Ad-GFP), as a control. As it can be 
observed in Fig. 2A, only the infection of fibroblasts with Ad-DN-AMPK adenovirus, 
prevented the AICAR-induced phosphorylation of endogenous AMPK at Thr172. 
We then analyzed protein degradation in Ad-GFP and AD-DN-AMPK infected 
cells that were treated with AICAR, lactacystin or a combination of these two 
compounds. Interestingly, fibroblasts infected with Ad-DN-AMPK adenovirus showed 
an increase in protein degradation, suggesting a positive role of AMPK in preventing 
protein degradation (Fig. 2B). However, in Ad-DN-AMPK infected fibroblasts, AICAR 
was still able to reduce protein degradation, what indicated that the action of AICAR 
was performed by an AMPK-independent mechanism. To confirm these results, we 
infected fibroblasts with adenovirus expressing a constitutively active form of AMPK 
(Ad-CA-AMPK; AMPK11-312 T172D; kindly provided by Dr. Pascal Ferre and Dr. F. 
Foufelle). As it is shown in Fig. 2B, treatment of these cells with AICAR reduced 
protein degradation to a similar extent as in cells infected with Ad-GFP adenovirus. The 
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fact that we did not observe differences in protein degradation when fibroblasts were 
infected with the adenovirus expressing the constitutively active form of AMPK (Ad-
CA-AMPK) may suggest that the basal activity of AMPK is sufficient to regulate 
protein degradation. At any rate, these results indicated that AICAR had AMPK-
independent inhibitory properties on protein degradation. 
When Ad-DN-AMPK infected cells were treated with lactacystin, protein 
degradation was reduced to similar levels to those obtained in Ad-GFP infected cells 
also treated with lactacystin. This result may suggest that the increase in protein 
degradation observed in Ad-DN-AMPK infected cells was due to increased proteasomal 
activity, what could be an indication of a positive role of AMPK in preventing 
proteasomal-dependent protein degradation. If Ad-DN-AMPK infected cells were 
treated with a combination of AICAR plus lactacystin, a further reduction in protein 
degradation was observed, confirming that AICAR could prevent protein degradation 
by an AMPK- and proteasomal-independent mechanism. 
 
3) AICAR treatment prevents lysosomal-dependent protein degradation by 
decreasing the amount of autophagic vacuoles. 
 Since the results presented so far suggested that AICAR had proteasomal-
independent inhibitory properties, we analyzed the lysosomal pathway in cells treated or 
not with AICAR. We observed that AICAR treatment decreased the number of 
autophagic vacuoles (Fig. 3A). Interestingly, this effect was also observed in cells 
infected with Ad-DN-AMPK adenovirus (Fig. 3A). This result indicated that the 
reduction in the amount of autophagic vacuoles produced by AICAR was AMPK-
independent. 
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 The inhibitory properties of AICAR on lysosomal-dependent protein 
degradation were confirmed by analysis of the post-translational modification of LC3-I, 
a cytosolic component of the autophagic pathway [18]. Upon autophagy stimulation, 
lipid conjugation of LC3-I leads to the formation of its autophagic-vesicle-associated 
form (LC3-II), which has an increased electrophoretic mobility on gels compared with 
LC3-I. The formation of the LC3-II conjugate is used as a marker of autophagy, since it 
decreases under conditions of low autophagic activity ([12], [19]) (see lanes of Fig. 3B 
corresponding to fibroblasts grown in Krebs-Henseleit medium with insulin and amino 
acids, IAa). When fibroblasts were grown in Krebs-Henseleit medium in the presence of 
AICAR, we observed a decrease in the formation of the LC3-II conjugate, what was an 
indication of inhibition of autophagy (Fig. 3B). 
 Autophagy is a highly regulated process that is activated under starvation 
conditions. On the contrary, it is inhibited when nutrient supplies are present ([6], [20], 
[21]). Insulin also inhibits autophagy by a mechanism involving activation of class I 
PI3-kinase, what leads to the subsequent activation of the Akt/PKB protein kinase by 
phosphorylation of Thr308 and Ser473, which eventually results in mTOR activation (a 
major negative regulator of autophagy) ([6], [20], [21]). Since, it has been recently 
suggested that AICAR could affect PI3-kinase activity [11], we checked whether 
AICAR treatment affected the phosphorylation status of Akt/PKB at Ser473, as a 
possible mechanism to explain the observed reduction in autophagy. However, AICAR 
treatment did not induced phosphorylation of Akt/PKB neither at Ser473 (Fig. 3C) nor 
at Thr308 (not shown). We repeated the analysis in cells that had been infected with the 
Ad-GFP adenovirus. In agreement with previous reports [22], adenovirus infection 
activates class I PI3-kinase leading to the phosphorylation of Akt/PKB at Ser473. 
However, AICAR treatment did not modify the amount of the phosphorylated form 
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(Fig. 3C). Therefore the inhibitory effects of AICAR on autophagy can not be explained 
by a stimulatory action on class I PI3-kinase activity. 
 It has been described that two distinct classes of PI3-kinases control autophagy 
in opposite directions. Whereas the action of class I PI3-kinase is inhibitory, class III 
PI3-kinase activates autophagy [23]. The activity of class III PI3-kinase depends on the 
formation of a multiprotein complex among class III PI3-kinase, beclin-1 and additional 
components (see [21], for review). In order to explain the inhibitory effects of AICAR 
on autophagy, we checked whether AICAR affected the formation of the complex 
between class III PI3-kinase and beclin-1. As shown in Fig. 3D, we observed that under 
conditions of AICAR treatment, beclin-1 could not co-immunoprecipitate with class III 
PI3-kinase, suggesting that the formation of the complex was defective under these 
conditions. Therefore, the effect of AICAR on decreasing lysosomal-dependent protein 
degradation could be explained by an impairment of class III PI3-kinase function. 
 
4) AMPK downregulates proteasomal-dependent protein degradation. 
 As we have described in Fig. 1, in addition to its lysosomal-dependent inhibitory 
properties, AICAR was also able to prevent protein degradation by a possible 
proteasomal-dependent mechanism. To analyze whether these effects of AICAR were 
dependent on AMPK activity, we analyzed the activity of the proteasome in wild type 
and AMPK subunit double knockout (1-/-, 2-/-) mouse embryonic fibroblasts 
(MEFs) under conditions of AMPK activation (treatment with either AICAR [9] or 
metformin [24]) (Fig. 4). We observed that in wild type MEFs, both AICAR and 
metformin treatments reduced the activity of the proteasome by around 20%. This 
inhibition was significant, although much lower that the one observed by the treatment 
of the same cells with lactacystin (97% inhibition). However, in the double knockout 
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1-/-, 2-/- MEFs, neither AICAR not metformin treatments decreased significantly the 
activity of the proteasome, which was however still sensitive to the action of lactacystin. 
These results indicated that activation of AMPK by either AICAR or metformin 
decreased proteasomal-dependent protein degradation. 
 
DISCUSSION 
In this work, we have examined the possible role of AMPK in regulating 
intracellular protein degradation. It has been reported that AMPK activation stimulates 
autophagy ([11], [12], [13]). The mechanism by which AMPK activates autophagy 
relies on the phosphorylation of the TSC1/TSC2 complex, a negative regulator of 
mTOR kinase; AMPK phosphorylates TSC2 leading to its activation [25], what in turn 
leads to the inhibition, via Rheb, of mTOR kinase, a major negative regulator of 
autophagy [21]. However, we have found that AICAR, a known AMPK activator, 
counteracts and reverses the effect of AMPK activation on autophagy by an AMPK-
independent mechanism. AICAR impairs the formation of a functional complex of 
beclin-1 with class III PI3-kinase, a major positive regulator of autophagy. In this way, 
the overall effect of AICAR is inhibition of autophagy. This AMPK-independent effect 
of AICAR is similar to the one described for 3-methyladenine, LY294002 and 
wortmannin, three inhibitors of autophagy [26]. These compounds inhibit both class I 
and class III PI3-kinases and, although by inhibiting class I PI3-kinase they should 
stimulate autophagy because this should lead to an inhibition of the mTOR pathway, 
their net effect is inhibition of autophagy since they inhibit the formation of 
phosphatidylinositol-3-phosphate by class III PI3-kinase, which is needed for autophagy 
[21]. 
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AMPK also affects proteasomal degradation, the other major intracellular 
protein degradation process. We have found that AMPK activation, either by AICAR or 
by an alternative activator such as metformin, leads to an inhibition of proteasomal 
function. This effect is dependent on AMPK activity since it is absent in cells that do 
not contain the two AMPK catalytic subunits. Although we have found that this effect is 
not severe when compared to the effects of proteasome inhibitors such as lactacystin, 
AMPK could be engaged in the fine tuning of proteasome activity under specific 
conditions. 
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FIGURE LEGENDS 
Fig. 1: AICAR affects protein degradation by proteasome-independent and lysosome-
independent mechanisms. Exponentially growing human fibroblasts were metabolically 
labeled with [3H]valine as described in Materials and Methods. Cells were then 
switched to Krebs-Henseleit (KH) medium for 4h with the following additions (final 
concentration): 0.5 mM AICAR, 20 M lactacystin (Lact), 20 mM NH4Cl plus 100 M 
leupeptin (NH4/Leup). The results are the mean from four separate experiments with 
duplicate samples and are expressed as percentage of the KH values (2.49% protein 
degraded per 1.5h). Bars indicate standard deviation and stars indicate differences 
which were found to be statistically significant at * p<0.05 and ** p<0.01 (n: 4). 
 
Fig. 2: Protein degradation under conditions of AMPK inactivation. A) Human 
fibroblasts were infected with adenovirus expressing a dominant negative form of 
AMPK (Ad-DN-AMPK) or with adenovirus expressing GFP (Ad-GFP) as control, or 
left uninfected. Twenty four hours later, the cells were incubated in Krebs-Henseleit 
medium in the absence or in the presence of AICAR (A, 0.5 mM) or lactacystin (L, 20 
M) for 4h. Cell lysates were analyzed by western blotting using anti-phosphoT172-
AMPK (upper panel), anti-AMPK (upper middle panel), anti-GFP (lower middle 
panel) and anti-actin (lower panel) antibodies. B) Human fibroblasts were labeled with 
[3H]valine for 48 h, and then they were infected with adenovirus encoding either a 
dominant negative (DN-AMPK) or a constitutively active (CA-AMPK) form of AMPK 
or GFP (GFP), and after 24h they were incubated in Krebs-Henseleit medium with the 
indicated additions as described in the legend to Fig. 1. Protein degradation was 
measured also as described in that figure. Results are the mean from four separate 
experiments with duplicated samples and are expressed as percentage of the Ad-GFP 
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infected cell values (1.44% protein degradation per 1.5h). Bars indicate standard 
deviation and stars indicate differences which were found to be statistically significant 
at * p<0.05 and ** p<0.01 (n: 4). 
 
Fig. 3: AICAR inhibits autophagy by an AMPK-independent mechanism. A) Human 
fibroblasts infected with adenovirus encoding GFP (Ad-GFP) or encoding a dominant 
negative form of AMPK (Ad-DN-AMPK) and incubated for 4h in Krebs-Henseleit 
medium without or with the addition of AICAR (0.5 mM) were analyzed by electron 
microscopic morphometry. Bars indicate standard deviation and stars indicate 
differences which were found to be statistically significant at * p<0.05 and *** p<0.001 
(n: 4). B) Cell extracts from human fibroblasts grown in Krebs-Henseleit without (KH) 
or with insulin and amino acids (IAa) medium treated or not with 0.5 mM AICAR for 4 
hours were analyzed by immunoblotting using anti-LC3 and anti-actin antibodies. 
AICAR decreased the ratios of LC3-II to actin from 1.14 to 0.70 and from 0.44 to 0.33 
in KH medium without or with IAa, respectively. C) Human fibroblasts were infected or 
not with adenovirus encoding GFP (Ad-GFP). Twenty four hours after the infection, 
fibroblasts were incubated for 4h in Krebs-Henseleit medium with or without the 
addition of AICAR (0.5 mM). Cell lysates were analyzed by western blotting using anti-
phosphoS473-Akt (upper panel), anti-Akt (middle panel) and anti-phosphoT172-AMPK 
(lower panel) antibodies. D) Human fibroblasts were incubated for 4h in Krebs-
Henseleit medium with or without the addition of AICAR (0.5 mM). Crude extracts 
(450 g) were immunoprecipitated with anti-class III PI3-kinase antibody and the 
immunoprecipitates analyzed by western blotting using anti-beclin-1 antibody. Crude 
extracts (CE, 75 g) were also analyzed using the same anti-class III PI3-kinase 
antibodies. 
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Fig. 4: AMPK downregulates proteasomal-dependent protein degradation. Proteasomal 
activity was measured in wild type and AMPK subunit double knockout (1-/-, 2-/-) 
MEFs incubated for 4h in Krebs-Henseleit medium with or without the addition of 0.5 
mM AICAR, 2 mM metformin (Metf) or 20 M lactacystin (Lact). Values are the mean 
of at least six independent experiments. Bars indicate standard deviation and stars 
indicate differences which were found to be statistically significant at ** p<0.01 and 
*** p<0.001 (n: 6). 
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